# Adebrelimab Neoadjuvant Treatment for Resectable ESCC

> **NCT07388095** · NA · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 22 (estimated)

## Conditions studied

- ESCC

## Interventions

- **DRUG:** Adebrelimab (PD-L1 inhibitor)

## Key facts

- **NCT ID:** NCT07388095
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-15
- **Primary completion:** 2027-02-28
- **Final completion:** 2028-02-28
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07388095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07388095, "Adebrelimab Neoadjuvant Treatment for Resectable ESCC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07388095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*